A Phase 1b/2 Study of GC012F, a Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects with Relapsed/Refractory Multiple Myeloma

Protocol No
GRACELL-GC012F-CD19-BCMA-001
Staff Member
Binod Dhakal
Phase
I/II
Summary

The purpose of this study is to find out about the safety and tolerability of the study drug and to determine if it is effective for the treatment of RRMM.
Objective
Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in subjects with r/r MM
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Cancer, Other Blood Related, Multiple Myeloma, Hematologic/Blood Related Cancers
ClinicalTrials.gov
https://www.clinicaltrials.gov/study/NCT05850234